Trial Profile

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Moxifloxacin (Primary) ; Amoxicillin; Doxycycline
Indications Acute exacerbations of chronic bronchitis; Bacterial infections
Focus Adverse reactions; Therapeutic Use
Acronyms SYMPROVE-III
Sponsors Bayer

Most Recent Events

02 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
02 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
14 Jul 2010 Planned end date changed from 1 Apr 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com